Highest-materiality recent filing
Xylem issues $1B in senior notes: $500M at 5.200% due 2033, $500M at 5.450% due 2036
$500M 5.200% Senior Notes due June 1, 2033; $500M 5.450% Senior Blue Notes due June 1, 2036.
Xylem shareholders elect nine directors, ratify auditor, approve advisory compensation and ESPP
All nine director nominees elected with at least 84.6% of votes cast; Jerome Peribere received 20.75M against.
Xylem Q1 adjusted EPS $1.12 (+9%), revenue $2.1B (+3%); FY guidance raised
Q1 orders $2.2B (+3% reported, flat organic); revenue $2.1B (+3% reported).
Xylem Board authorizes $1.5B share repurchase program with no expiration
New share repurchase program authorizes up to $1.5 billion in common stock purchases.
Xylem Q4 adjusted EPS $1.42 (+20% YoY), full-year revenue $9.0B record; dividend raised 8%
Q4 revenue $2.4B (+6% reported, +4% organic); orders $2.4B (+9%, +7% organic).
Xylem Q3 2025: revenue up 8% to $2.3B; adj. EPS $1.37, +23%; raises full-year guidance
Revenue $2.3B, +8% reported (+7% organic); net income $227M ($0.93 EPS).
Xylem Q2 revenue $2.3B (+6% organic); EPS $0.93; adj. EPS $1.26; raises FY guidance
Revenue $2.3B, up 6% reported and organic; net income $226M ($0.93/share), up 16%.
All nine director nominees elected: Earl R. Ellis, Robert F. Friel, Lisa Glatch, Victoria D. Harker, Mark D. Morelli, Jerome A. Peribere, Matthew F. Pine, Lila Tretikov, Uday Yadav.
Xylem Q1 revenue $2.1B, adj EPS $1.03, beats expectations; reaffirms FY guidance
Revenue $2.1B, up 2% reported and 3% organic; book-to-bill ratio above 1.0.
Xylem beats Q4 guidance; revenue $2.3B, adj. EPS $1.18; raises dividend 11%
Q4 revenue $2.3B, up 7% organic; orders $2.2B, up 7%; GAAP EPS $1.34 (+22%), adjusted EPS $1.18 (+19%).
Xylem confirms FY2024 results in-line/above guidance; announces restructuring with $95-115M charges
On Jan 28, 2025, management committed to a restructuring plan with workforce reductions across all businesses.
Xylem director Jeanne Beliveau-Dunn to not seek re-election at 2025 annual meeting
Jeanne Beliveau-Dunn informed Board on Jan 10, 2025 of her decision not to stand for re-election.
Xylem Q3 revenue $2.1B, adjusted EPS $1.11 (+12% YoY); narrows FY guidance
Revenue $2.1B, up 1% reported and organic; orders up 8%.
Xylem appoints Meredith Emmerich as Applied Water President; Cerwinka steps down
Franz Cerwinka steps down as SVP & President, Applied Water effective Oct 21; advisor until March 31, 2025.
Xylem Q2 revenue $2.2B (+26% reported, +9% organic); EPS $0.80, adj EPS $1.09; raises FY guidance
Net income $194M ($0.80 EPS), up 78%; adjusted EPS $1.09, up 11%.
Xylem shareholders elect all 10 directors, approve say-on-pay and auditor at 2024 annual meeting
All 10 director nominees elected, with support ranging from 88.4% to 95.0% of votes cast (excluding broker non-votes).
Xylem beats Q1 estimates, raises FY revenue and adjusted EPS guidance
Q1 revenue of $2.0B (+40% reported, +7% organic); orders $2.2B (+43% reported, +3% organic).
On January 10, 2025, Jeanne Beliveau-Dunn informed the Board of Directors (the “Board”) of Xylem Inc. (the “Company”) of her decision not to stand for re-election as a Director of the Company at the Company’s 2025 annual meeting of shareholders (“2025 Annual Meeting”).
Effective October 21, 2024, Franz W. Cerwinka will cease to serve as Xylem Inc.’s (the “Company”) Senior Vice President and President, Applied Water and Xylem Business Transformation.
Max materiality 0.85 · Median 0.70 · Most common event earnings